Corient Private Wealth
RCUS icon

Corient Private Wealth’s Arcus Biosciences RCUS Stock Holding History

Corient Private Wealth’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.82M Buy
59,127
+34,984
+145% +$865K ﹤0.01% 1450
2026
Q1 		$521K Buy
24,143
+1,577
+7% +$34.1K ﹤0.01% 2006
2025
Q4 		$538K Buy
22,566
+392
+2% +$8K ﹤0.01% 1833
2025
Q3 		$302K Buy
22,174
+107
+0.5% +$1.11K ﹤0.01% 2109
2025
Q2 		$180K Buy
+22,067
New +$188K ﹤0.01% 2259

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Corient Private Wealth's RCUS Position: Q2 2026 in Review

Corient Private Wealth increased its Arcus Biosciences (RCUS) stake by 145% in Q2 2026, buying an estimated $865K and bringing the position to 59,127 shares worth $1.82M. The position accounts for ﹤0.01% of the portfolio, ranked #1450.

Corient Private Wealth first reported a position in RCUS in Q2 2025 and has held it in 5 quarters since. 231 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • Corient Private Wealth held 59,127 shares of Arcus Biosciences worth $1.82M as of Q2 2026.
  • Corient Private Wealth bought 34,984 Arcus Biosciences shares in Q2 2026, an estimated $865K.
  • Arcus Biosciences made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #1450 holding.
  • Corient Private Wealth first reported a position in Arcus Biosciences in Q2 2025 and has held it in 5 quarters since.
  • 231 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.